TB-500 is frequently discussed alongside thymosin beta-4, but the terms should not automatically be treated as interchangeable. Naturally occurring thymosin beta-4 is a 43-amino-acid protein involved in actin regulation, cell migration, inflammation, and tissue-repair signaling.
An analytical investigation of a product labeled TB-500 identified it as the acetylated 17–23 fragment of thymosin beta-4, with the sequence Ac-LKKTETQ. This is only a short portion of the full-length thymosin beta-4 molecule. Biological findings obtained using full-length thymosin beta-4 therefore cannot automatically be attributed to the shorter TB-500 fragment.
Full-length thymosin beta-4 has been evaluated in human wound research. In a randomized phase 2 study involving 73 participants with venous stasis ulcers, topical thymosin beta-4 demonstrated a safety profile considered comparable to placebo. Researchers reported a possible wound-healing signal at one concentration, but the study was exploratory and involved topical full-length thymosin beta-4 — not the TB-500 fragment.
Research limitations
When discussing TB-500, it is important to identify the exact peptide sequence used in a study. Research involving full-length thymosin beta-4, isolated peptide fragments, topical products, and injectable research materials represents different formulations and cannot be combined as though they were the same intervention.
References
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta-4 identified in TB-500. Drug Testing and Analysis. 2012;4:733–738. DOI: 10.1002/dta.1402.
- Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences. 2010;1194:207–212. DOI: 10.1111/j.1749-6632.2010.05490.x.
